title: Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.
abstract: The population pharmacokinetics of pyrimethamine (PYR) and sulfadoxine (SDX) for a group of 32 children with congenital toxoplasmosis was investigated by nonparametric modeling analysis. A one-compartment model was used as the structural model, and individual pharmacokinetic parameters were estimated by Bayesian modeling. PYR (1.25 mg/kg of body weight) and SDX (25 mg/kg) were administered orally every 10 days for 1 year, with adjustment of the dose to body weight every 3 months. Drug concentrations were measured by high-performance liquid chromatography. A total of 101 measurements in serum were available for both drugs. Mean absorption rate constants, volumes of distribution, elimination rate constants, and half-lives were 0.915 h(-1), 4.379 liters/kg, 0.00839 h(-1), and 5.5 days for PYR and 1.659 h(-1), 0.392 liters/kg, 0.00526 h(-1), and 6.6 days for SDX, respectively. Wide interindividual variability was observed. The estimated minimum and maximum concentrations of PYR in serum differed 8- and 25-fold among patients, respectively, and those of SDX differed 4- and 5-fold, respectively. Increases in the concentration of PYR were observed for eight children, and increases in the SDX concentration were observed for seven children. Serum PYR-SDX concentrations are unpredictable even when the dose is standardized for body weight. The concentrations of the PYR-SDX combination that are most efficacious for children have not yet been established. A model such as ours, associated with long-term follow-up, is needed to study the correlation between exposure to these two drugs and clinical outcome in children.
authors.affiliation: Department of Pharmacy, Croix-Rousse Hospital, 103 Grande Rue de la Croix-Rousse, 69317 Lyon Cedex 04, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Corvaisier
authors.forename: Bruno
authors.initials: B
authors.lastname: Charpiat
authors.forename: Cyril
authors.initials: C
authors.lastname: Mounier
authors.forename: Martine
authors.initials: M
authors.lastname: Wallon
authors.forename: Gilles
authors.initials: G
authors.lastname: Leboucher
authors.forename: Mounzer
authors.initials: M
authors.lastname: Al Kurdi
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Chaulet
authors.forename: François
authors.initials: F
authors.lastname: Peyron
mesh_terms: D000981:Antiprotozoal Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001499:Bayes Theorem; D001835:Body Weight / Q000502:physiology; D002648:Child; D002851:Chromatography, High Pressure Liquid; D005500:Follow-Up Studies; D006207:Half-Life; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008954:Models, Biological; D011153:Population; D011739:Pyrimethamine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013413:Sulfadoxine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000981:Antiprotozoal Agents; D013413:Sulfadoxine; D011739:Pyrimethamine